一项关于Praliciguat在局灶节段性肾小球硬化症(FSGS)受试者中的研究
一项2期随机、双盲、安慰剂对照研究,旨在评估普拉利瓜特在经活检确诊为局灶性节段性肾小球硬化患者中的疗效和安全性
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial 24 week treatment period. Following this double-blind period, all participants will receive praliciguat in an open-label period for an additional 24 weeks. Participants responding to treatment will be offered the opportunity to participate in the long-term safety extension study.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Akebia Therapeutics
- 电话号码:16178446128
- 邮箱:trials@akebia.com
学习地点
-
-
California
-
Chula Vista、California、美国、91910
- 招聘中
- Investigator Site #2
-
Garden Grove、California、美国、92844
- 招聘中
- Investigator Site #28
-
Los Angeles、California、美国、90022
- 招聘中
- Investigator Site #14
-
San Dimas、California、美国、91773
- 招聘中
- Investigator Site #12
-
-
Colorado
-
Arvada、Colorado、美国、80002
- 招聘中
- Investigator Site #13
-
-
Florida
-
Boca Raton、Florida、美国、33431
- 招聘中
- Investigator Site #17
-
Coral Springs、Florida、美国、33071
- 招聘中
- Investigator Site #6
-
Hialeah、Florida、美国、33010
- 招聘中
- Investigator Site #25
-
Miami、Florida、美国、33172
- 招聘中
- Investigator Site #7
-
Orlando、Florida、美国、32806
- 招聘中
- Investigator Site #8
-
-
Georgia
-
Augusta、Georgia、美国、30901
- 招聘中
- Investigator Site #29
-
Lawrenceville、Georgia、美国、30046
- 招聘中
- Investigator Site # 1
-
-
Illinois
-
Chicago、Illinois、美国、60643
- 终止
- Investigator Site #3
-
-
Kentucky
-
Louisville、Kentucky、美国、40205
- 招聘中
- Investigator Site #11
-
-
Maryland
-
Catonsville、Maryland、美国、21229
- 招聘中
- Investigator Site #32
-
-
Massachusetts
-
Worcester、Massachusetts、美国、01608
- 招聘中
- Investigator Site #24
-
-
Michigan
-
Livonia、Michigan、美国、48152
- 招聘中
- Investigator Site #15
-
Pontiac、Michigan、美国、48341
- 招聘中
- Investigator Site #10
-
-
New York
-
Valhalla、New York、美国、10595
- 招聘中
- Investigator Site #27
-
-
North Carolina
-
New Bern、North Carolina、美国、28562
- 招聘中
- Investigator Site #16
-
Shelby、North Carolina、美国、28150
- 招聘中
- Investigator Site #31
-
-
Ohio
-
Cleveland、Ohio、美国、44106
- 招聘中
- Investigator Site #20
-
-
Pennsylvania
-
Bethlehem、Pennsylvania、美国、18017
- 招聘中
- Investigator Site #30
-
Bridgeville、Pennsylvania、美国、15017
- 招聘中
- Investigator Site #19
-
Butler、Pennsylvania、美国、16001
- 招聘中
- Investigator Site #22
-
-
South Carolina
-
Goose Creek、South Carolina、美国、29445
- 招聘中
- Investigator Site #23
-
-
Tennessee
-
Chattanooga、Tennessee、美国、37404
- 招聘中
- Investigator Site #4
-
-
Texas
-
Arlington、Texas、美国、76015
- 招聘中
- Investigator Site #5
-
Dallas、Texas、美国、75231
- 招聘中
- Investigator Site #9
-
Dallas、Texas、美国、75230
- 招聘中
- Investigator Site #21
-
Houston、Texas、美国、48152
- 招聘中
- Investigator Site #18
-
-
Virginia
-
Roanoke、Virginia、美国、24014
- 招聘中
- Investigator Site #26
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria (Part A):
- UPCR ≥1 (g/g) during screening.
- On maximally tolerated ACEi or ARB per principal investigator discretion within 1 month of informed consent.
- Estimated glomerular filtration rate ≥25 milliliters per minute per 1.73 square meters by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
- Kidney biopsy collected within 5 years of screening consistent with FSGS or kidney biopsy collected ≥5 years prior to screening consistent with FSGS plus the presence of a pathogenic gene mutation known to be associated with FSGS.
Exclusion Criteria (Part A):
- Collapsing FSGS in the kidney biopsy report.
- Sickle cell disease.
- HbA1c >8%.
- Uncontrolled hypertension (≥160/100 millimeters of mercury).
Inclusion Criteria (Part B):
1. Participants responding to treatment will be offered the opportunity to participate in the long-term safety extension study.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Praliciguat (Part A)
Praliciguat will be administered daily with dose escalation to a target dose during a 24-week double-blind period, followed by a 24-week open-label treatment period. |
Oral Tablet |
|
安慰剂比较:Placebo (Part A)
Matching placebo will be administered daily for 24 weeks |
Oral Tablet |
|
实验性的:Experimental: Long-term safety extension praliciguat (Part B)
Praliciguat will be administered daily |
Oral Tablet |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Change from Baseline in urine protein-to-creatinine ratio (UPCR) (Part A)
大体时间:Baseline (Day 1) and up to Week 24
|
Baseline (Day 1) and up to Week 24
|
|
Proportion of participants with TEAEs, serious adverse events (SAEs), and treatment-emergent adverse events of special interest (AESIs). (Part A)
大体时间:Time Frame: Up to Week 52
|
Time Frame: Up to Week 52
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants with Partial Remission at Week 24 (Part A)
大体时间:Up to Week 24
|
Partial remission is defined as 40% UPCR reduction and UPCR<1.5 gram/gram (g/g). |
Up to Week 24
|
|
Plasma concentrations of praliciguat (Part A)
大体时间:Week 24, Week 32, and Week 36
|
Week 24, Week 32, and Week 36
|
|
|
Incidence of TEAEs, SAEs, and AESIs in the long-term safety extension (Part B)
大体时间:From Week 48 Part A through study completion
|
From Week 48 Part A through study completion
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- AKB-1973-CI-0001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.